Saturday 17 October 2026
Export KMTS’s income statement to Excel — free account
Kestra Medical Technologies, Ltd.
KMTS Healthcare Medical Instruments & Supplies
Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025. In the quarter to July 2026, revenue grew 59.9%, EPS fell 50.0%, free cash flow fell 17.8% and total debt rose 74.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
27.24
1.44
−5.02%
Follow KMTS
| Jul '26 | Apr '26 | Jan '26 | Oct '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+6 more quarters Free account |
P/S ratio |
12.53 | 11.80 | 16.68 | 18.94 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(41.40) | (59.97) | (76.02) | (76.69) | |
P/B ratio |
6.01 | 4.32 | 4.85 | 8.57 | |
Price to Tangible BV |
6.01 | 4.32 | 4.85 | 8.57 | |
EV/Sales |
11.34 | 10.19 | 13.70 | 17.14 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(13.80) | (11.86) | (13.18) | (14.69) | |
EV/FCF |
(9.84) | (8.29) | (9.56) | (11.15) | |
Quick Ratio |
4.44 | 4.19 | 7.08 | 5.20 | |
Current Ratio |
4.69 | 4.41 | 7.32 | 5.47 | |
Net Debt/EBITDA |
3.56 | 4.20 | 7.71 | 4.62 | |
Debt/Assets |
20.87% | 11.90% | 11.14% | 16.97% | |
Debt/Equity |
0.33 | 0.16 | 0.15 | 0.26 | |
Asset Turnover |
0.35 | 0.29 | 0.39 | 0.60 | |
Operating CF/Net income |
0.73 | 0.48 | 0.54 | 0.56 | |
Capex/Depreciation |
(3.82) | (3.60) | (4.05) | (2.61) | |
Interest Coverage |
(19.52) | (21.32) | (18.41) | (16.70) | |
Research and Development Expense of Revenue |
21.94% | 19.67% | 20.25% | 21.62% | |
Selling, General and Administrative Expense of Revenue |
156.14% | 172.47% | 173.91% | 169.74% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
30.73% | 35.98% | 41.17% | 38.35% | |
Graham Net Nets |
0.08 | 0.11 | 0.16 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.70%) | (11.68%) | (15.84%) | (16.23%) | |
Free Cash Flow Yield |
(9.20%) | (10.42%) | (8.60%) | (8.12%) | |
Revenue per Share |
0.53 | 0.53 | 0.44 | 0.44 | |
Operating CF per Share |
(0.55) | (0.35) | (0.33) | (0.36) | |
Capex per Share |
(0.14) | (0.18) | (0.18) | (0.14) | |
Free Cash Flow per Share |
(0.69) | (0.52) | (0.51) | (0.50) | |
Cash per Share |
3.40 | 3.63 | 5.22 | 3.41 | |
Shareholders Equity per Share |
3.80 | 4.79 | 5.16 | 3.19 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.80 | 4.79 | 5.16 | 3.19 | |
Free Cash Flow |
(40.63) | (28.38) | (28.28) | (25.76) | |
Working Capital |
178.00 | 171.99 | 271.13 | 159.66 | |
Capital Expenditures |
(8.33) | (9.66) | (9.92) | (7.42) | |
Net Current Asset Value |
101.28 | 123.55 | 222.71 | 112.79 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.27 | 0.34 | 0.40 | 0.33 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.33 | 11.31 | 7.35 | — | |
Average Payables |
22.27 | 25.63 | 23.96 | — | |
Average Assets |
306.83 | 327.10 | 212.65 | 123.35 | |
Average Common Equity |
203.26 | 232.53 | 39.31 | — |
Columns are period end dates · fundamentals updated 2 Oct 2026